Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) announced today that its subsidiaries have entered into a Memorandum of Agreement with Invitrx Therapeutics, Inc. (INVITRX) to advance two proposed workstreams: the manufacture and sale of GENREVER cosmetic products in the United States and the potential supply of concentrated exosomes and conditioned media for clinics and an in-hospital cell processing center and laboratory in Indonesia.
The collaboration builds upon a six-year commercial relationship under which Instinct Bio has sourced principal raw materials from INVITRX. Under the proposed framework, Instinct Bio intends to license the GENREVER trademark, Artisans Production will contribute proprietary formulations and raw materials, and INVITRX is expected to manufacture GENREVER products at its U.S. GMP manufacturing facility. The parties aim to position GENREVER as a premium Japanese cosmetics brand in the U.S. market, subject to regulatory requirements.
Additionally, the parties will collaborate to support Indonesia’s emerging regenerative medicine ecosystem. INVITRX is expected to supply concentrated exosomes and conditioned media for proposed clinics and an in-hospital cell processing center and laboratory, as the parties evaluate opportunities to establish a localized regenerative medicine platform in one of Asia’s rapidly growing healthcare markets.
Tomoki Nagano, Chief Executive Officer of Instinct Bio, stated: "This collaboration represents an important step in our strategy to expand Instinct Bio’s international platform. By bringing together the GENREVER brand, Artisans Production’s proprietary formulations and INVITRX’s U.S. GMP manufacturing capabilities, we believe we are creating a strong foundation for future growth in both the United States and Southeast Asia."
The parties intend to negotiate definitive commercial agreements covering manufacturing, supply, commercialization and other operating arrangements while progressing regulatory assessments. The MOA establishes a framework, and there is no assurance that definitive agreements will be entered into or that the proposed initiatives will be completed.
Instinct Bio is a biotechnology company focused on regenerative medicine, longevity-related technologies and advanced therapeutic platforms. INVITRX is a U.S.-based biotechnology company that operates a GMP manufacturing facility and develops cell-derived biological materials, including concentrated exosomes and conditioned media. More information is available at https://instinct-biot.com/.
